阿培利司单药治疗PI3K通路改变的经治晚期乳腺癌:一项II期研究
该II期多队列研究评估阿培利司单药在晚期PI3K通路突变的ER+HER2-和三阴性乳腺癌中的疗效。意向治疗ER+队列的客观缓解率为30%,临床获益率为36%。治疗期间PI3K通路突变循环肿瘤DNA水平下降与缓解和生存改善相关,基线ESR1突变亦与获益相关。
要点
- 阿培利司单药在经治PI3K通路突变ER+乳腺癌中显示疗效,客观缓解率30%,临床获益率36%。
- 治疗第8周PI3K通路突变ctDNA较基线下降与部分缓解、临床获益及无进展生存改善相关(HR 0.24)。
- 基线血浆ESR1突变与临床获益及无进展生存改善相关(HR 0.22)。
核心结论
- 阿培利司单药在经治PI3K通路突变ER+乳腺癌中显示疗效。
- 治疗期间血浆PIK3CA突变动态和基线血浆ESR1突变是预测阿培利司获益的候选生物标志物。
研究设计与样本
- 一项II期多队列研究,评估阿培利司单药在晚期PI3K通路突变ER+HER2-和三阴性乳腺癌患者中的疗效。
主要发现
- 意向治疗ER+队列的客观缓解率为30%,临床获益率为36%。
- 治疗第8周PI3K通路突变ctDNA较基线下降与部分缓解、临床获益及无进展生存改善显著相关(HR 0.24;95%CI 0.083-0.67,P=0.0065)。
- 基线血浆ESR1突变与临床获益及无进展生存改善相关(HR 0.22;95%CI 0.078-0.60,P=0.003)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: There is limited knowledge on the benefit of the α-subunit-specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor-positive (ER+) HER2- and triple-negative breast cancer (TNBC). We conducted a phase II multicohort study of alpelisib monotherapy in patients with advanced PI3K pathway mutant ER+HER2- and TNBC. In the intention-to-treat ER+ cohort, the overall response rate was 30% and the clinical benefit rate was 36%. A decline in PI3K pathway mutant circulating tumor DNA (ctDNA) levels from baseline to week 8 while on therapy was significantly associated with a partial response, clinical benefit, and improved progression-free-survival [HR 0.24; 95% confidence interval (CI), 0.083-0.67, P = 0.0065]. Detection of ESR1 mutations at baseline in plasma was also associated with clinical benefit and improved progression-free survival (HR 0.22; 95% CI, 0.078-0.60, P = 0.003). SIGNIFICANCE: Alpelisib monotherapy displayed efficacy in heavily pretreated ER+ breast cancer with PIK3CA mutations. PIK3CA mutation dynamics in plasma during treatment and ESR1 mutations detected in plasma at baseline were candidate biomarkers predictive of benefit from alpelisib, highlighting the utility of ctDNA assays in this setting. This article is highlighted in the In This Issue feature, p. 2007.
引用
- Savas P, Lo LL, Luen SJ, et al. Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. Cancer Discov. 2022. PMID: 35771551. doi:10.1158/2159-8290.CD-21-1696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。